Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM).

Carmen Balana,Antonio Lopez-Pousa,Alfonso Berrocal,Ricardo Yaya Tur,Ana Herrero,Jose-luis García,Javier Martin-Broto,Manuel Benavides,Miguel Cerdá-Nicolás,Rosa Ballester,Josep Balart,Jaume Capellades

Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM).

2004

Carmen Balana
Antonio Lopez-Pousa
Alfonso Berrocal
Ricardo Yaya Tur
Ana Herrero
Jose-luis García
Javier Martin-Broto
Manuel Benavides
Miguel Cerdá-Nicolás
Rosa Ballester
Josep Balart
Jaume Capellades

This phase II study evaluates the activity of temozolomide and cisplatin administered before radiation therapy in newly diagnosed glioblastoma multiforme patients, in terms of response, time to progression and survival.

Keywords:

Pathology
Temozolomide
Cancer
Cisplatin
Phases of clinical research
Radiation therapy
Oncology
Measurable Disease
Internal medicine
Chemotherapy
Central nervous system disease
Medicine
Neurology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations